Travere Therapeutics, Inc. TVTX Business Segments — R&D
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Travere Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.
The official record: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Travere Therapeutics, Inc.'s business segments — r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Travere Therapeutics, Inc.'s business segments — R&D?
- Travere Therapeutics, Inc. (TVTX) reported business segments — R&D of $57.09M in Q1 2026.
- How has Travere Therapeutics, Inc.'s business segments — R&D changed year-over-year?
- Travere Therapeutics, Inc.'s business segments — R&D increased by 21.8% year-over-year, from $46.89M to $57.09M.
- What is the long-term trend for Travere Therapeutics, Inc.'s business segments — R&D?
- Over 3 years (2022 to 2025), Travere Therapeutics, Inc.'s business segments — R&D has grown at a -3.2% compound annual growth rate (CAGR), from $227.33M to $206.01M.
- What does business segments — R&D mean?
- This metric aggregates all costs associated with the discovery, development, and clinical testing of the company's therapeutic pipeline. It is a critical measure of the company's commitment to long-term innovation and future product commercialization.